Our Fisher Clinical ServicesSM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. Please update your bookmark.
How Can You Avoid the Fallout From Incompatibility Between Your API and Its Formulation?
In drug development, designing a formulation for a drug product (a tablet, for example) calls for careful attention to both the physical and chemical properties of the active pharmaceutical ingredient (API or drug substance). It also requires awareness that certain physical attributes, such as particle size distribution of the drug substance, can change with processing conditions and changes in the synthesis route that is employed.
Find out how a pharmaceutical company can recognize both unfavorable drug substance properties and incompatibility between an API and its formulation to avoid potential risks to the patient as well as costly interruptions during development.
Author: Matthew Jones, Sr. Scientist, Head of Crystallization Lab, Patheon